ziv-aflibercept
Selected indexed studies
- Ziv-Aflibercept. (, 2006) [PMID:29999888]
- Intravitreal Ziv-Aflibercept: A Comprehensive Review. (Semin Ophthalmol, 2019) [PMID:31314638]
- Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. (Int J Retina Vitreous, 2020) [PMID:31956432]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. (2024) pubmed
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. (2021) pubmed
- Intravitreal Ziv-Aflibercept: A Comprehensive Review. (2019) pubmed
- Ziv-Aflibercept. (2006) pubmed
- Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. (2020) pubmed
- Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. (2017) pubmed
- Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer. (2014) pubmed
- Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. (2013) pubmed
- Ziv-aflibercept in metastatic colorectal cancer. (2014) pubmed
- Ziv-aflibercept in macular disease. (2015) pubmed